CD274 and non-small cell lung carcinoma: The ASCO-NSO-ASTRO guidelines recommend that patients with asymptomatic brain metastases and immunotherapy-naïve, PD-L1-positive NSCLC should consider platinum + pemetrexed + pembrolizumab and recommend a multifaceted discussion of the risks and benefits of local therapy.